GLP-1 Receptor Agonists and Psoriatic Disease: A Deep Dive

Written by The Life Science Feed Editorial Team · Published 19 June 2026 · Edited by Mara Voss

> The intersection of metabolic dysfunction and inflammatory dermatoses presents a clinical challenge. Glucagon-like peptide-1 (GLP-1) receptor agonists, established therapies for type 2 diabetes and obesity,1 are now being investigated for their potential to modify psoriatic disease. This analysis examines the current understanding of GLP-1 agonism in the context of psoriasis and psoriatic arthritis, focusing on mechanistic plausibility and clinical observations.

KEY TAKEAWAYS

- The Pivot: GLP-1 receptor agonists, beyond their metabolic indications, are being explored for immunomodulatory effects in psoriatic disease.
- The Data: Observational studies and mechanistic insights suggest a reduction in inflammatory markers and potential improvement in skin and joint symptoms.
- The Action: Clinicians should be aware of the potential dual benefits in patients with co-morbid type 2 diabetes/obesity and psoriatic disease, though dedicated trials are needed.

Psoriasis and psoriatic arthritis are chronic inflammatory conditions with a significant burden of metabolic comorbidities, including obesity, type 2 diabetes mellitus, and cardiovascular disease. The shared inflammatory pathways, particularly involving cytokines such as TNF-alpha, IL-17, and IL-23, provide a biological rationale for investigating therapies with pleiotropic effects. GLP-1 receptor agonists (GLP-1 RAs), such as semaglutide and liraglutide, are synthetic analogues of the human incretin hormone GLP-1. Their primary actions involve glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and appetite reduction, leading to improved glycaemic control and weight loss. Beyond these metabolic effects, GLP-1 RAs have demonstrated anti-inflammatory properties in various preclinical models and some human studies, which has prompted interest in their role in immune-mediated diseases like psoriasis. Psoriasis affects approximately 2-3% of the global population, with psoriatic arthritis developing in up to 30% of individuals with psoriasis. The systemic inflammation characteristic of these conditions contributes to an increased risk of metabolic syndrome, non-alcoholic fatty liver disease, and major adverse cardiovascular events. Given the high prevalence of these comorbidities, therapeutic strategies that address both the dermatological/rheumatological manifestations and the associated metabolic dysfunction are highly desirable. GLP-1 RAs, with their established efficacy in metabolic disease management and emerging evidence of anti-inflammatory actions, represent a compelling area of investigation for this patient population.

Mechanistic Basis and Clinical Observations

The anti-inflammatory effects of GLP-1 RAs are thought to be mediated through several pathways. GLP-1 receptors are expressed on various immune cells, including macrophages, T cells, and dendritic cells. Activation of these receptors can lead to a reduction in pro-inflammatory cytokine production and an increase in anti-inflammatory mediators. For example, GLP-1 RAs have been shown to suppress NF-κB signalling, a key pathway in inflammation, and to reduce the expression of adhesion molecules involved in immune cell trafficking. In the context of psoriasis, which is driven by a Th17-mediated inflammatory response, modulating these pathways could theoretically mitigate disease activity.

Clinical observations supporting this hypothesis largely stem from analyses of patients with co-morbid type 2 diabetes or obesity who are treated with GLP-1 RAs. These reports have described improvements in psoriatic skin lesions and joint symptoms. For instance, some retrospective cohort studies have indicated that patients initiating GLP-1 RA therapy experienced a reduction in Psoriasis Area and Severity Index (PASI) scores or a decrease in the need for systemic psoriasis treatments. These are observational data, however, and are subject to confounding by indication and other biases. The weight loss induced by GLP-1 RAs itself can improve psoriasis severity, as adipose tissue is a source of pro-inflammatory cytokines, and obesity is an independent risk factor for more severe psoriatic disease. Distinguishing between direct immunomodulatory effects of GLP-1 RAs and indirect effects mediated by weight loss is challenging in these observational settings.

Dedicated prospective studies specifically evaluating GLP-1 RAs for psoriatic disease are limited. A small number of pilot studies and case series have reported improvements in PASI scores and C-reactive protein (CRP) levels in patients with psoriasis treated with GLP-1 RAs, independent of significant weight loss in some instances. These studies, while hypothesis-generating, typically involve small patient numbers and lack control groups, limiting the generalisability and strength of their conclusions. The duration of follow-up in these reports is also often insufficient to assess long-term disease modification.

Limitations and Future Directions

The current evidence base for GLP-1 RAs as disease-modifying agents in psoriasis and psoriatic arthritis is primarily indirect and observational. While the mechanistic rationale is plausible and anecdotal clinical improvements have been reported, robust, randomised, placebo-controlled trials are required to establish efficacy and safety specifically for psoriatic disease. Such trials would need to account for the confounding effect of weight loss and assess specific dermatological and rheumatological endpoints, such as PASI, Psoriasis Area and Severity Index 75 (PASI75), and American College of Rheumatology (ACR) response criteria. Furthermore, understanding which subsets of patients with psoriatic disease might benefit most (e.g., those with significant metabolic comorbidities versus those without) is critical. The long-term impact on disease progression, joint damage, and cardiovascular outcomes in this patient population also warrants investigation.

Beyond the need for controlled trials, further research should focus on elucidating the precise molecular mechanisms by which GLP-1 RAs exert their immunomodulatory effects in the context of psoriatic disease. This could involve detailed analyses of cytokine profiles, immune cell phenotypes, and gene expression patterns in skin and synovial tissue before and after GLP-1 RA therapy. The potential for combination therapies, where GLP-1 RAs are used alongside existing biologics or small molecule inhibitors, also warrants exploration, particularly in patients with refractory disease or significant metabolic burden.

For a comprehensive understanding of dermatological conditions pertinent to this discussion, readers may wish to consult the authoritative Oxford Handbook of Medical Dermatology.

CLINICAL IMPLICATIONS

The emerging data on GLP-1 receptor agonists and psoriatic disease present a compelling, albeit preliminary, narrative. For clinicians managing patients with both type 2 diabetes or obesity and psoriasis, the potential for a single agent to address multiple comorbidities is attractive. However, it is imperative to distinguish between a beneficial side effect of a metabolic drug and a targeted disease-modifying therapy. Prescribing GLP-1 RAs solely for psoriasis without a primary metabolic indication is not currently supported by robust evidence.

The pharmaceutical industry, particularly companies like Novo Nordisk and Eli Lilly with significant investments in GLP-1 RA development, will undoubtedly be watching this space closely. Should dedicated trials demonstrate efficacy in psoriatic disease, it could open a substantial new market, potentially positioning these agents as an early-line therapy for a subset of patients, particularly those with metabolic syndrome. However, the cost-effectiveness compared to established biologics for psoriasis would need careful consideration.

For patients, this represents a potential future avenue for treatment, especially for those struggling with the dual burden of inflammatory skin disease and metabolic dysfunction. It offers a glimmer of hope for a more holistic approach to their care. Yet, it is crucial that expectations are managed; the current evidence does not warrant off-label prescribing for psoriasis alone. The call for well-designed, adequately powered clinical trials is not merely academic; it is essential for informing evidence-based practice and ensuring patient safety and optimal outcomes.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Buonanno S, et al. The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review. Inflamm Res. 2025;74(1):167. doi:10.1007/s00011-025-02140-2
2. 2. Lin L, et al. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial. J Dermatolog Treat. 2022;33(3):1428-1434. doi:10.1080/09546634.2020.1826392
3. 3. Karacabeyli D, et al. Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review. J Clin Rheumatol. 2024;30(1):26-31. doi:10.1097/RHU.0000000000001949
4. 4. Haberman RH, et al. Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis-Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts. Arthritis Rheumatol. 2026. doi:10.1002/art.70170
5. 5. Ciancio G, et al. Glucagon-like peptide-1 receptor agonists in psoriasis and psoriatic arthritis: emerging evidence and future research opportunities. Front Immunol. 2026;17:1744308. doi:10.3389/fimmu.2026.1744308

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com